Paxneury and Tuzulby should be granted Europe-wide marketing authorizations for treating attention-deficit hyperactivity, the ...

Intuniv (guanfacine hydrochloride prolonged release tablets) is licensed for children and adolescents of 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to ...